Member Info for SamJSung

From the ADVFN Board

http://www.proactiveinvestors.co.uk/companies/stocktube/9664/synairgen-says-its-drug-well-tolerated-in-phase-ii-trial-9664.html

Marsden on COPD ..- coming days or weeks for the biomarker data to be released .Next two weeks then ?

If that's good that 14/15p resistance level will be well and truly history .

Media Release        14 June 2018 PHARMAXIS ‘BEST IN CLASS’ LOXL2 PROGRAM ATTRACTS STRONG PHARMA INTEREST AS IT ENTERS FINAL STAGE OF PHASE 1 TRIALS  First stage of phase 1 studies demonstrate a best in class profile for lysyl oxidase like 2 (LOXL2) inhibitors with two compounds achieving significant and long lasting inhibition of LOXL2 enzyme after a single oral dose.  Final stages of phase 1 studies and phase 2 enabling toxicity studies are due to complete in Q3 2018.    Pharmaxis conducts multiple partnering discussions with multinational Pharma companies at BIO 2018

A lot of your unasked questions can be answered VIA http://www.synairgen.com/media/1378/synairgen-march-2018-21_03_18.pdf From the March 18 Corporate Presentation Summary/Outlook � Inhaled IFN-β programme o Phase II in COPD commenced February 2018 o First data due in Q2 2018 � LOXL2 collaboration with Pharmaxis o In Phase I, results expected summer 2018 o Licensing transaction targeted by Pharmaxis for 2018 � Seeking new opportunities � Company performing in line with strategy The Board are totally incentivised to increase shareholder value.. The SNG Board in total has just under 10% of the SNG share capital.. made up of both Options and Fully Paid shares.. Woodford Investment Managers also hold 23% of SNG share capital..

A lot of your unasked questions can be answered VIA http://www.synairgen.com/media/1378/synairgen-march-2018-21_03_18.pdf From the March 18 Corporate Presentation Summary/Outlook � Inhaled IFN-β programme o Phase II in COPD commenced February 2018 o First data due in Q2 2018 � LOXL2 collaboration with Pharmaxis o In Phase I, results expected summer 2018 o Licensing transaction targeted by Pharmaxis for 2018 � Seeking new opportunities � Company performing in line with strategy The Board are totally incentivised to increase shareholder value.. The SNG Board in total has just under 10% of the SNG share capital.. made up of both Options and Fully Paid shares.. Woodford Investment Managers also hold 23% of SNG share capital..

The Phase 1 study for SNG001 was carried out successfully in preparation for the Astra Z acquisition of its rights (now handed back to SNG as the resultant data from its Phase 2 trials of SNG001 proved inconclusive due to small number of patient outcomes.. this has now been addressed for the current Phase 2 trial using new patient selection methodology and associated new test methodologies) The favourable programmes may possiblly relate to the wider use of LOXL2 .. the SNG agreement (for its 17% stake in LOXL2 covers (I Believe) all uses of the compound and all potential reveunes both upfront and commercial etc.. across all areas e.g NASH etc.. The other favourable programmes refer (i suspect) to R&D of various compounds that could have signifcant impact in both current e.g COPD / ASTHMA areas and other yet to be determined areas... Commercial confidentiality will keep this information as vague as possible.. t The LOXL2 programme is in itself an attractive asset and SNG believethe wholly-owned IFN-beta asset has huge potential. The rest of 2018 , , will see the safety data read out for IFN-beta in COPD (anticipated Q2) and in the summer Pharmaxis is expected to provide an update on the LOXL2 inhibitor programme. For information .. since the current published Annual Report Leonard Licht (A Private Investor) has increased his holding in SNG and now holds 6,650,000 ordinary shares This represents 7.27% of SNG share capital.

I have to say that information on SNG is limited primarily to Company announcements.. e.g Updates, and Interviews with people like Richard Marsden CEO... Broker Reports are also limited (see below for what I believe is an extract from house Broker FinnCap.. I have spoken with Richard Marsden a number of times.. Very much on the ball, open (as best he can) and determined that SNG delivers very signifcant returns to SNG shareholders... Broker finnCap reckons the stock is worth 35p based on a discounted cash flow (DCF) valuation that that puts 17p and 18p a share price tags on, respectively, SNG001 and LOXL2. �The slightly higher-than-expected year-end cash of �6.8m provides an ample cash runway through 2019,� added analyst Mark Brewer. His risk-adjust DCF valuation will rise to �41mln, or 45p a share following the successful completion of a pilot safety study of SNG001.

http://www.synairgen.com/media/1378/synairgen-march-2018-21_03_18.pdf

From the ADVFN Board.. https://www.youtube.com/embed/K_WBCeIYD-s 4 minutes in on LOXL - quite compelling ..

From the ADVFN Bulletin Board... A positve interview with CEO Pharmaxis http://www.proactiveinvestors.com.au/companies/stocktube/9289/pharmaxis-has-key-drivers-in-place-for-short-and-long-term-value-creation-9289.html

From todays Proactive Investors Australia LOXL2 inhibitor program receiving interest from large pharma Pharmaxis� anti fibrotic LOXL2 inhibitor program is reaching its conclusion and attracting strong interest from multiple potential large pharma partners. Phase I clinical trials that commenced in the second half of 2017 have completed the single ascending dose stage and are proceeding into the final multiple ascending dose stages this quarter before reporting in the September quarter. Three-month tox studies and the scale-up of manufacturing have commenced so that a potential partner will be able to commence phase II studies without delay.

I sometimes wonder why certain sales occur at what I would regard as non optimum prices..It then crosses my mind that Market Makers are smart individuals who may manipulate prices to suit themselves or favoured clients.. Lowering the SNG share price to hit Stop Loss Accounts .. which they have visibility of .. possibly to fulfil large orders in the background.. Is todays series of sales exactly that to help achieve / support the largest single purchase I have seen of 500K shares... Is this further accumulation by one of the existing large shareholders or a new stakebuilder recognising the significant potential of SNG..

Latest RNS states Leonard Licht, a private investor, now holds 4,600,000 ordinary shares.. 5.03% ... his previous recorded holding was 3,700,000 4.1% of SNG share Capital .. We now have a good idea of who was the buyer of 100K bundles of SNG shares...A man who believes the future for SNG is extremely bright !

Just released... The potential for both Share Price and Medical outcomes from both Interferon B and LOXL2 remain significant.... 2018 is likely to prove a pivotal year..

Pharmaxis closed at 0.32 AUD (up 4.92% ) to reach its 52 week high...

Is the accumulation of 100K share parcels in SNG linked in any way to what appears to be a rising Pharmaxis share price... Pharmaxis closed at 0.285 AUD a rise of 3.64% on the previous day.. and heading towards its 52 week high of 0.31... A sign that LOXL2 is perfoming well in its trials perhaps ?

Another 100K purchase today.. reported at 17.49... executed at 15.49 at 14p....the 4th such purchase of a 100K block Since the beginning of 2018 ...No RNS has been issued .. so possibly a new stakebuilder to be added to the share register..

From ohisay on the ADVFN notice board... Finncaps target price will be a risked evaluation of each of SNG's prospects - a bit like the way that Oil exploration companies are evaluated - typically they might do risking of 10 - 20% success outcomes for example on particular fields . So if both of the prospects both come in that 20% gets towards 100% and the 35p will be correspondingly much higher (and vice versa of course) - all other things being equal.

By StockMarketWire | Wed, 7th February 2018 - 08:20 finnCap today reaffirms its corporate investment rating on Synairgen PLC (LON:SNG) and set its price target at 35p.

Another 100K Purchase today... reported at 14:31 executed at 12.31 at 14p. This follows previous 100K purchases on 22nd Jan at 11.5p, and 13.75p on the 9th Feb 2018... A true believer in SNG's future prospects.

From PDT on the ADVFN Board https://www.youtube.com/watch?v=y-s0ZaNsO5Q Mentioned interest from around 10 potential partners and upfronts in the region of $50m dollars. SNG get 17% of that. Confident on a deal after Phase 1 completes mid-year. Very positive :)